{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:53:31Z","timestamp":1794027211089,"version":"4.8.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40265-025-02258-x","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:12:26Z","timestamp":1763529146000},"page":"79-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms"],"prefix":"10.1007","volume":"86","author":[{"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"11","key":"2258_CR1","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s40121-024-01044-8","volume":"13","author":"B Grabein","year":"2024","unstructured":"Grabein B, Arhin FF, Daikos GL, et al. Navigating the current treatment landscape of metallo-\u03b2-lactamase-producing Gram-negative infections: what are the limitations? Infect Dis Ther. 2024;13(11):2423\u201347.","journal-title":"Infect Dis Ther"},{"issue":"2","key":"2258_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ofid\/ofad046","volume":"10","author":"HS Sader","year":"2023","unstructured":"Sader HS, Mendes RE, Carvalhaes CG, et al. Changing epidemiology of carbapenemases among carbapenem-resistant Enterobacterales from United States hospitals and the activity of aztreonam-avibactam against contemporary Enterobacterales (2019\u20132021). Open Forum Infect Dis. 2023;10(2):1\u201310.","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"2258_CR3","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s10096-023-04645-2","volume":"42","author":"MG Wise","year":"2023","unstructured":"Wise MG, Karlowsky JA, Mohamed N, et al. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa\/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019\u20132021. Eur J Clin Microbiol Infect Dis. 2023;42(9):1135\u201343.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"2258_CR4","first-page":"1","volume":"11","author":"JF Timsit","year":"2022","unstructured":"Timsit JF, Wicky PH, de Montmollin E. Treatment of severe infections due to metallo-betalactamases Enterobacterales in critically ill patients. Antibiotics (Basel). 2022;11(2):1\u201314.","journal-title":"Antibiotics (Basel)."},{"key":"2258_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jgar.2023.12.027","volume":"36","author":"GM Rossolini","year":"2024","unstructured":"Rossolini GM, Arhin FF, Kantecki M. In vitro activity of aztreonam-avibactam and comparators against metallo-\u03b2-lactamase-producing Enterobacterales from ATLAS global surveillance program, 2016\u20132020. J Glob Antimicrob Resist. 2024;36:123\u201331.","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"2258_CR6","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S1473-3099(20)30868-9","volume":"22","author":"MF Mojica","year":"2022","unstructured":"Mojica MF, Rossi MA, Vila AJ, et al. The urgent need for metallo-\u03b2-lactamase inhibitors: an unattended global threat. Lancet Infect Dis. 2022;22(1):e28-34.","journal-title":"Lancet Infect Dis"},{"key":"2258_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/IDR.S246174","volume":"14","author":"X Tan","year":"2021","unstructured":"Tan X, Kim HS, Baugh K, et al. Therapeutic options for metallo-\u03b2-lactamase-producing Enterobacterales. Infect Drug Resist. 2021;14:125\u201342.","journal-title":"Infect Drug Resist."},{"key":"2258_CR8","unstructured":"European Medicines Agency. Emblaveo: EU summary of product characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/emblaveo-epar-product-information_en.pdf. Accessed 17 Oct 2025."},{"key":"2258_CR9","unstructured":"European Medicines Agency. List of nationally authorised medicinal products - aztreonam. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/psusa\/aztreonam-list-nationally-authorised-medicinal-products-psusa00010178201808_en.pdf. Accessed 17 Oct 2025."},{"issue":"2","key":"2258_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/jac\/dkh358","volume":"54","author":"A Bonnefoy","year":"2004","unstructured":"Bonnefoy A, Dupuis-Hamelin C, Steier V, et al. In vitro activity of AVE1330A, an innovative broad-spectrum non-\u03b2-lactam \u03b2-lactamase inhibitor. J Antimicrob Chemother. 2004;54(2):410\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"29","key":"2258_CR11","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1073\/pnas.1205073109","volume":"109","author":"DE Ehmann","year":"2012","unstructured":"Ehmann DE, Jahi\u0107 H, Ross PL, et al. Avibactam is a covalent, reversible, non\u2013\u03b2-lactam \u03b2-lactamase inhibitor. Proc Natl Acad Sci USA. 2012;109(29):11663\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2258_CR12","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1128\/AAC.00568-10","volume":"54","author":"T Stachyra","year":"2010","unstructured":"Stachyra T, P\u00e9chereau MC, Bruneau JM, et al. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-\u03b2-lactam \u03b2-lactamase inhibitor. Antimicrob Agents Chemother. 2010;54(12):5132\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"2258_CR13","unstructured":"US FDA. Avycaz: US prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/206494Orig1s014correctedlbl.pdf. Accessed 17 Oct 2025."},{"key":"2258_CR14","unstructured":"European Medicines Agency. Zavicefta: EU summary of product characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zavicefta-epar-product-information_en.pdf. Accessed 17 Oct 2025."},{"issue":"6","key":"2258_CR15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley M. Ceftazidime-avibactam: a review in the treatment of serious Gram-negative bacterial infections. Drugs. 2018;78(6):675\u201392.","journal-title":"Drugs"},{"issue":"9","key":"2258_CR16","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1093\/jac\/dkv132","volume":"70","author":"R Singh","year":"2015","unstructured":"Singh R, Kim A, Tanudra MA, et al. Pharmacokinetics\/pharmacodynamics of a \u03b2-lactam and \u03b2-lactamase inhibitor combination: a novel approach for aztreonam\/avibactam. J Antimicrob Chemother. 2015;70(9):2618\u201326.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2258_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2023.106776","volume":"61","author":"DM Livermore","year":"2023","unstructured":"Livermore DM, Mushtaq S, Vickers A, et al. Activity of aztreonam\/avibactam against metallo-\u03b2-lactamase-producing Enterobacterales from the UK: impact of penicillin-binding protein-3 inserts and CMY-42 \u03b2-lactamase in Escherichia coli. Int J Antimicrob Agents. 2023;61(5):1\u20137.","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"2258_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00472-17","volume":"61","author":"JA Karlowsky","year":"2017","unstructured":"Karlowsky JA, Kazmierczak KM, de Jonge BLM, et al. In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015. Antimicrob Agents Chemother. 2017;61(9):1\u201313.","journal-title":"Antimicrob Agents Chemother"},{"key":"2258_CR19","unstructured":"US FDA. Emblaveo (aztreonam and avibactam) for injection: US prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217906Orig1s000lbl.pdf. Accessed 17 Oct 2025."},{"key":"2258_CR20","unstructured":"Pfizer. ATLAS (Antimicrobial Testing Leadership and Surveillance). 2025. https:\/\/atlas-surveillance.com. Accessed 17 Oct 2025."},{"issue":"3","key":"2258_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/jac\/dkaa504","volume":"76","author":"HS Sader","year":"2021","unstructured":"Sader HS, Carvalhaes CG, Arends SJR, et al. Aztreonam\/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. J Antimicrob Chemother. 2021;76(3):659\u201366.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2258_CR22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10096-022-04400-z","volume":"41","author":"HS Sader","year":"2022","unstructured":"Sader HS, Mendes RE, Arends SJR, et al. Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019\u20132020). Eur J Clin Microbiol Infect Dis. 2022;41(3):477\u201387.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"2258_CR23","first-page":"1","volume":"5","author":"HS Sader","year":"2023","unstructured":"Sader HS, Castanheira M, Kimbrough JH, et al. Aztreonam\/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019\u201321). JAC Antimicrob Resist. 2023;5(2):1\u201310.","journal-title":"JAC Antimicrob Resist."},{"issue":"4","key":"2258_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2024.107113","volume":"63","author":"HS Sader","year":"2024","unstructured":"Sader HS, Carvalhaes CG, Kimbrough JH, et al. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020\u20132022). Int J Antimicrob Agents. 2024;63(4):1\u20137.","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"2258_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antibiotics12111591","volume":"12","author":"D Pi\u00e9rard","year":"2023","unstructured":"Pi\u00e9rard D, Hermsen ED, Kantecki M, et al. Antimicrobial activities of aztreonam-avibactam and comparator agents against Enterobacterales analyzed by ICU and non-ICU wards, infection sources, and geographic regions: ATLAS Program 2016\u20132020. Antibiotics. 2023;12(11):1\u201327.","journal-title":"Antibiotics"},{"issue":"6","key":"2258_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antibiotics13060564","volume":"13","author":"HS Sader","year":"2024","unstructured":"Sader HS, Mendes RE, Kimbrough JH, et al. Activity of aztreonam\/avibactam and recently approved \u03b2-lactamase inhibitor combinations against Enterobacterales and Pseudomonas aeruginosa from intensive care unit and non-intensive care unit patients. Antibiotics. 2024;13(6):1\u201314.","journal-title":"Antibiotics"},{"issue":"11","key":"2258_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01433-20","volume":"64","author":"HS Sader","year":"2020","unstructured":"Sader HS, Duncan LR, Arends SJR, et al. Antimicrobial activity of aztreonam-avibactam and comparator agents when tested against a large collection of contemporary Stenotrophomonas maltophilia isolates from medical centers worldwide. Antimicrob Agents Chemother. 2020;64(11):1\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2258_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00297-20","volume":"64","author":"M Biagi","year":"2020","unstructured":"Biagi M, Lamm D, Meyer K, et al. Activity of aztreonam in combination with avibactam, clavulanate, relebactam, and vaborbactam against multidrug-resistant Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2020;64(12):1\u201311.","journal-title":"Antimicrob Agents Chemother"},{"key":"2258_CR29","doi-asserted-by":"publisher","first-page":"e0069324","DOI":"10.1128\/aac.00693-24","volume":"68","author":"L Tao","year":"2024","unstructured":"Tao L, Dahlquist A, Harris H, et al. Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-\u03b2-lactamase-producing carbapenem-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2024;68:e0069324.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2258_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12866-021-02108-2","volume":"21","author":"Q Lin","year":"2021","unstructured":"Lin Q, Zou H, Chen X, et al. Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro. BMC Microbiol. 2021;21(1):1\u20136.","journal-title":"BMC Microbiol"},{"issue":"7","key":"2258_CR31","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1128\/AAC.01989-12","volume":"57","author":"JL Crandon","year":"2013","unstructured":"Crandon JL, Nicolau DP. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-\u03b2-lactamase producers. Antimicrob Agents Chemother. 2013;57(7):3299\u2013306.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2258_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/jac\/dkab346","volume":"77","author":"S Mushtaq","year":"2021","unstructured":"Mushtaq S, Vickers A, Ellaby N, et al. Selection and characterization of mutational resistance to aztreonam\/avibactam in \u03b2-lactamase-producing Enterobacterales. J Antimicrob Chemother. 2021;77(1):98\u2013111.","journal-title":"J Antimicrob Chemother"},{"key":"2258_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2022.926209","volume":"12","author":"W Yu","year":"2022","unstructured":"Yu W, Shen P, Chen Y, et al. Epidemiology and genomic characteristics of bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae with decreased susceptibility to aztreonam\/avibactam in China. Front Cell Infect Microbiol. 2022;12:1\u20135.","journal-title":"Front Cell Infect Microbiol"},{"issue":"11","key":"2258_CR34","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1093\/jac\/dkab279","volume":"76","author":"RE Mendes","year":"2021","unstructured":"Mendes RE, Doyle TB, Streit JM, et al. Investigation of mechanisms responsible for decreased susceptibility of aztreonam\/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. J Antimicrob Chemother. 2021;76(11):2833\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"2258_CR35","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1093\/jac\/dkaa021","volume":"75","author":"H Periasamy","year":"2020","unstructured":"Periasamy H, Joshi P, Palwe S, et al. High prevalence of Escherichia coli clinical isolates in India harbouring four amino acid inserts in PBP3 adversely impacting activity of aztreonam\/avibactam. J Antimicrob Chemother. 2020;75(6):1650\u20131.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2258_CR36","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/jac\/dku568","volume":"70","author":"RA Alm","year":"2015","unstructured":"Alm RA, Johnstone MR, Lahiri SD. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam\/avibactam: role of a novel insertion in PBP3. J Antimicrob Chemother. 2015;70(5):1420\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"2258_CR37","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00389-17","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Kashikar A, Brown CA, et al. Unusual Escherichia coli PBP 3 insertion sequence identified from a collection of carbapenem-resistant Enterobacteriaceae tested in vitro with a combination of ceftazidime-, ceftaroline-, or aztreonam-avibactam. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.00389-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"2258_CR38","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00592-18","author":"KM Kazmierczak","year":"2018","unstructured":"Kazmierczak KM, Bradford PA, Stone GG, et al. In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against OXA-48-carrying Enterobacteriaceae isolated as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance program from 2012 to 2015. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/AAC.00592-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2258_CR39","doi-asserted-by":"publisher","first-page":"e01659","DOI":"10.1128\/AAC.01659-20","volume":"64","author":"M Sadek","year":"2020","unstructured":"Sadek M, Juhas M, Poirel L, et al. Genetic features leading to reduced susceptibility to aztreonam-avibactam among metallo-\u03b2-lactamase-producing Escherichia coli isolates. Antimicrob Agents Chemother. 2020;64(12):e01659-e1720.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2258_CR40","doi-asserted-by":"publisher","first-page":"e00821","DOI":"10.1128\/mSystems.00821-20","volume":"5","author":"K Ma","year":"2020","unstructured":"Ma K, Feng Y, McNally A, et al. Struggle to survive: the choir of target alteration, hydrolyzing enzyme, and plasmid expression as a novel aztreonam-avibactam resistance mechanism. mSystems. 2020;5(6):e00821-e920.","journal-title":"mSystems."},{"key":"2258_CR41","unstructured":"European Medicines Agency. Emblaveo: EPAR assessment report. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/emblaveo-epar-public-assessment-report_en.pdf. Accessed 17 Oct 2025."},{"issue":"6","key":"2258_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.02446-17","volume":"62","author":"WW Nichols","year":"2018","unstructured":"Nichols WW, Newell P, Critchley IA, et al. Avibactam pharmacokinetic\/pharmacodynamic targets. Antimicrob Agents Chemother. 2018;62(6):1\u201315.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2258_CR43","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01950-24","volume":"69","author":"R Xie","year":"2025","unstructured":"Xie R, Rogers H, Chow JW, et al. Population pharmacokinetic\/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients. Antimicrob Agents Chemother. 2025;69(8):e0195024.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2258_CR44","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/jac\/dkz497","volume":"75","author":"OA Cornely","year":"2020","unstructured":"Cornely OA, Cisneros JM, Torre-Cisneros J, et al. Pharmacokinetics and safety of aztreonam\/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. J Antimicrob Chemother. 2020;75(3):618\u201327.","journal-title":"J Antimicrob Chemother"},{"key":"2258_CR45","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","volume":"25","author":"Y Carmeli","year":"2024","unstructured":"Carmeli Y, Cisneros JM, Paul M, et al. Aztreonam\u2013avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial. Lancet Infect Dis. 2024;25:218\u201330.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"2258_CR46","doi-asserted-by":"publisher","first-page":"dlaf131","DOI":"10.1093\/jacamr\/dlaf131","volume":"7","author":"GL Daikos","year":"2025","unstructured":"Daikos GL, Cisneros JM, Carmeli Y, et al. Aztreonam-avibactam for the treatment of serious infections caused by metallo-beta-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE). JAC Antimicrob Resist. 2025;7(4):dlaf131.","journal-title":"JAC Antimicrob Resist."},{"issue":"4","key":"2258_CR47","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521\u201347.","journal-title":"Clin Microbiol Infect"},{"key":"2258_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","author":"PD Tamma","year":"2024","unstructured":"Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae403.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2258_CR49","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jinf.2019.06.011","volume":"79","author":"L Sorli","year":"2019","unstructured":"Sorli L, Luque S, Li J, et al. Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: dose is critical. J Infect. 2019;79(3):253\u201361.","journal-title":"J Infect"},{"issue":"3","key":"2258_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12030437","volume":"12","author":"J Rychl\u00ed\u010dkov\u00e1","year":"2023","unstructured":"Rychl\u00ed\u010dkov\u00e1 J, Kub\u00ed\u010dkov\u00e1 V, Suk P, et al. Challenges of colistin use in ICU and therapeutic drug monitoring: a literature review. Antibiotics. 2023;12(3):437.","journal-title":"Antibiotics"},{"issue":"12","key":"2258_CR51","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1093\/cid\/cis270","volume":"54","author":"P Prasad","year":"2012","unstructured":"Prasad P, Sun J, Danner RL, et al. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012;54(12):1699\u2013709.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2258_CR52","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","volume":"72","author":"M Falcone","year":"2021","unstructured":"Falcone M, Daikos GL, Tiseo G, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-\u03b2-lactamase-producing Enterobacterales. Clin Infect Dis. 2021;72(11):1871\u20138.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"2258_CR53","first-page":"S798","volume":"12","author":"S Raber","year":"2025","unstructured":"Raber S, Xie R, Soto E, et al. Pharmacokinetic\/pharmacodynamic (PK\/PD) target attainment analyses for aztreonam-avibactam dosing regimens. Open Forum Infect Dis. 2025;12(Suppl 1):S798\u20139.","journal-title":"Open Forum Infect Dis"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02258-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02258-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02258-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T03:03:34Z","timestamp":1768359814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02258-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2258"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02258-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Matt Shirley is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}